DSIP Injection: What It Is, How It's Studied, and What to Know

A DSIP injection is a dose of delta sleep-inducing peptide delivered under the skin, into a vein, or into the nose. It has been studied as a possible sleep-promoting compound since the 1970s, but it is not FDA-approved for human use and has no established human dosage. Product sold online is labeled as a research chemical, not a medicine.

What Is DSIP?

DSIP stands for delta sleep-inducing peptide, a nine-amino-acid chain first isolated from rabbit brain tissue in 1977. The peptide has since been detected in human blood, cerebrospinal fluid, and several organs.

Researchers originally linked it to slow-wave (delta) sleep, the deep stage associated with physical recovery. Later work explored possible connections to stress hormones, pain signaling, and opioid withdrawal.

One practical problem is speed. DSIP is cleared from blood within minutes, which makes consistent delivery difficult and helps explain why study results vary so widely.

What the Research Shows About Sleep

The human evidence for DSIP is old, small, and mixed. Most published studies date from the 1980s and 1990s and involved only a handful of participants each.

• Some reported shorter time to fall asleep or better subjective sleep quality.
• Others found no meaningful difference from placebo.
• Trials in withdrawal, pain, and stress produced similarly inconsistent results.

No major medical organization recognizes DSIP as a treatment for insomnia or any other condition. People with persistent sleep problems have better-studied options, including cognitive behavioral therapy for insomnia (CBT-I) and FDA-approved prescription medications.

DSIP Peptide Injection Dosage: Why No Standard Exists

Search for a dsip peptide injection dosage and you will find numbers that range from a few micrograms to several milligrams, with few sources agreeing. That spread reflects the absence of a validated protocol rather than a well-known range.

Published research used many different amounts and routes and produced inconsistent outcomes, so no dose was ever carried forward into standard practice. Dosages printed on vendor websites are marketing copy, not clinical guidance.

The table below describes how each route was used in research. It is not a dosing guide.

Route	How it was used in research	Main limitation
Intravenous (IV)	Delivered directly into the bloodstream in early clinical studies	Requires a clinical setting; very short duration of action
Subcutaneous (SC)	Injected into fatty tissue in later studies	Variable absorption; no standardized amount established
Intranasal	Sprayed into the nose in a subset of trials	Inconsistent absorption between users

Reconstitution and Storage

DSIP is typically sold as a lyophilized powder that must be dissolved before use. The diluent most commonly paired with research peptides is bacteriostatic water for injection, which contains 0.9% benzyl alcohol to inhibit bacterial growth in a multi-dose vial.

Colloquially shortened to bac water for injection, that diluent is not the same as sterile saline or plain sterile water. Benzyl alcohol makes it unsuitable for certain uses, including intrathecal and neonatal applications.

Lyophilized powder should be kept cold, dry, and out of light. Once reconstituted, peptide solutions are usually refrigerated and used within a few weeks, though vendor guidance varies and none of it is FDA-reviewed.

Legal Status and Safety

DSIP is not approved by the FDA, and it cannot legally be sold as a drug for human use in the United States. Products labeled "DSIP" are marketed as research chemicals that are "not for human consumption," which means no regulator verifies their identity, purity, or sterility.

Side effects reported in the limited literature include drowsiness, headache, nausea, dizziness, and irritation at the injection site. Because long-term safety data do not exist, the risks of repeated use are unknown.

Regulatory status depends on the specific product, not the molecule alone. Many researchers compare pt-141 nasal spray vs injection to understand how route changes a peptide's behavior, and the same molecule used in those products is FDA-approved as Vyleesi injection for hypoactive sexual desire disorder in premenopausal women.

Product	FDA status	Approved use
DSIP	Not approved	None; sold as a research chemical
Bremelanotide (Vyleesi)	Approved	Hypoactive sexual desire disorder in premenopausal women
Melatonin	Regulated as a dietary supplement	Not approved as a drug
Suvorexant (Belsomra)	Approved	Insomnia

Safer Next Steps

Talk with a healthcare professional before injecting any unapproved peptide. A clinician can screen for sleep apnea, thyroid problems, depression, and other conditions that mimic insomnia, and can recommend treatments backed by real safety data.

If you already have a vial, do not assume the label is accurate. Independent testing of research-chemical peptides has repeatedly found the wrong peptide, the wrong concentration, and bacterial contamination.

DSIP remains an interesting research question and an unproven human therapy. The gap between those two things is where most of the risk sits.

COMMON QUESTIONS

Frequently Asked Questions

Is DSIP legal to buy in the United States?

DSIP is not FDA-approved and cannot legally be sold as a drug for human use in the US. Vendors work around that by labeling it a research chemical that is "not for human consumption." Purchasing it for personal injection is a legal gray area, and the product itself is unregulated.

How is a DSIP injection typically given?

In published research, DSIP was administered intravenously, subcutaneously, and intranasally. Subcutaneous injection is the format most commonly discussed online. No dose, route, or schedule has been validated in humans.

Does DSIP actually help with sleep?

The evidence is weak. Small, older studies produced mixed results, and no large modern trial has confirmed a benefit for insomnia. Anyone with ongoing sleep problems should ask a clinician about CBT-I or FDA-approved options instead.